Filing Flows › ARS Pharmaceuticals (SPRY) › Q2 2026 › vs Q1 2026
ARS Pharmaceuticals (SPRY) Q2 2026 vs Q1 2026 (quarter over quarter)
ARS Pharmaceuticals's revenue rose $11.0M (+48%) from $22.7M in Q1 2026 to $33.7M in Q2 2026. The biggest changes: Product +$8.8M (+50%); Revenue Under Supply Agreements +$4.7M (+170%); Revenue Under Collaboration Agreements −$2.4M (-98%).
ARS Pharmaceuticals, Q2 2026: revenue $33.7M (+114% year over year), operating margin -182.6%, net loss $62.3M, operating cash flow −$60.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $26.2M | $17.5M | $8.8M | +50% |
| Revenue Under Supply Agreements | $7.4M | $2.7M | $4.7M | +170% |
| Revenue Under Collaboration Agreements | $57K | $2.5M | −$2.4M | -98% |
| Revenue | $33.7M | $22.7M | $11.0M | +48% |
| Net loss | $62.3M | $60.6M | $1.7M | +3% |
| Costs & expenses | $96.0M | $83.3M | $12.7M | +15% |
| Operating costs | $95.1M | $82.8M | $12.3M | +15% |
| Interest & other, net | $874K | $473K | $401K | +85% |
| Research & development | $4.7M | $4.3M | $362K | +8% |
| SG&A | $77.6M | $72.2M | $5.4M | +7% |
| Other operating costs | $12.8M | $6.3M | $6.6M | +104% |
| Operating cash sources | $73.7M | $52.8M | $21.0M | +40% |
| Depreciation & amortization | $416K | $397K | $19K | +5% |
| Share-based compensation | $12.4M | $7.4M | $5.0M | +67% |
| Cash used in operations | $60.9M | $44.9M | $16.0M | +36% |
| Net loss absorbed | $62.3M | $60.6M | $1.7M | +3% |
| Working capital & other | $11.4M | −$7.9M | $19.3M | — |
Questions
How much did ARS Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
ARS Pharmaceuticals's revenue rose $11.0M (+48%) from $22.7M in Q1 2026 to $33.7M in Q2 2026.
What drove ARS Pharmaceuticals's revenue change in Q2 2026?
Product +$8.8M (+50%); Revenue Under Supply Agreements +$4.7M (+170%); Revenue Under Collaboration Agreements −$2.4M (-98%).